Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8-89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6-10); HADS median (range) total score = 13 (5-21); DLQI mean score = 16 (2-27); EQ-5D-3L median (range) = 57 (30-99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0-17.1), HADS total score median (range) = 2 (0-10) and improved quality of life EQ-5D-3L median (range) = 89 (92-60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile.